CXD-101 is under clinical development by Celleron Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CXD-101’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 11 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
In addition, the same event on 11 Mar 2022 decreased CXD-101’s LoA and PTSR for Primary Mediastinal B-Cell Lymphoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CXD-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CXD-101 (AZD-9468) is under development for the treatment of solid tumors including colorectal cancer and haematological cancers including diffuse large B-cell lymphoma, peripheral T-cell lymphomas, primary mediastinal B-cell lymphoma. The drug candidate acts by targeting enzyme histone deacetylase (HDAC). The drug candidate is administered by oral route. It is developed in conjunction with its proprietary CancerNav predictive biomarker platform. It was also under development for lung, cervical, breast, pancreatic, ovarian and ENT cancer and haematological cancers including Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma (AITL), multiple myeloma, follicular lymphoma, Gray Zone non-Hodgkin lymphoma and Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma).
Celleron Therapeutics overview
Celleron Therapeutics is involved in providing healthcare solutions that offer cancer therapies. The company’s products include T-ARG-et, CXD101, and Bromo-FIX. Its CXD101 is novel HDACinhibitor with multiple positive differentiation properties from competing products for predictive biomarkers. Celleron Therapeutics also develops and markets cancer therapies and technologies that improve the performance of regular cancer treatments. The company develops biomarkers using epigenetic techniques that match drugs to responsive disease and technologies are used to develop a new class of mechanism-based cancer drugs to improve the success rates of treatment and reduce the side effects. It provides services such as drug development, cancer research, and clinical practice services. Celleron Therapeutics is headquartered in Oxford, the UK.
Quick View CXD-101 LOA Data
|Highest Development Stage|